SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hawley, C.J.
Right arrow Articles by Echlin, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hawley, C.J.
Right arrow Articles by Echlin, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Safety and tolerability of combined treatment with moclobemide and SSRIs: a preliminary study of 19 patients

C.J. Hawley

Queen Elizabeth Hospital, Welwyn Garden City, Hertfordshire AL7 4HQ

S. Ratnam

Central Middlesex Hospital, Acton Lane, London NW10 7NN, UK

H.A. Pattinson

Queen Elizabeth Hospital, Welwyn Garden City, Hertfordshire AL7 4HQ

S.J. Quick

Queen Elizabeth Hospital, Welwyn Garden City, Hertfordshire AL7 4HQ

D. Echlin

Queen Elizabeth Hospital, Welwyn Garden City, Hertfordshire AL7 4HQ

Nineteen major depressed patients, resistant to previous pharmacotherapies, were treated by the addition of moclobemide (up to 600 mg/day) to paroxetine or fluoxetine (20 mg/day) for 6 weeks in an open study to assess the adverse events and tolerability. There were 77 emergent events, insomnia, headache, nausea and dizziness being the most common. Many events were rated as severe. The high rate of adverse events suggests that there may be clinically significant interactions between moclobemide and SSRIs. However, the uncontrolled data on effectiveness is encouraging and the combination deserves further attention as a strategy for treating intractable major depression.

Key Words: SSRI • paroxetine • fluoxetine • moclobemide • combination • treatment

Journal of Psychopharmacology, Vol. 10, No. 3, 241-245 (1996)
DOI: 10.1177/026988119601000311
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement